Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 SEK | +11.43% | 0.00% | -22.82% |
04-29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
04-29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Sales 2022 | 1.14M 106K 144K | Sales 2023 | 1.58M 146K 198K | Capitalization | 80.25M 7.41M 10.11M |
---|---|---|---|---|---|
Net income 2022 | -168M -15.52M -21.17M | Net income 2023 | -309M -28.55M -38.94M | EV / Sales 2022 | 460 x |
Net cash position 2022 | 68.47M 6.33M 8.63M | Net cash position 2023 | 72.5M 6.7M 9.14M | EV / Sales 2023 | 4.92 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-0.22
x | Employees | 11 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.11% |
Latest transcript on Immunovia AB
1 day | +11.43% | ||
3 months | -27.79% | ||
6 months | +41.56% | ||
Current year | -22.82% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
1st Jan change | Capi. | |
---|---|---|
-13.30% | 18.53B | |
-42.12% | 2.82B | |
+20.51% | 1.91B | |
+1.29% | 1.65B | |
+27.52% | 1.25B | |
-14.61% | 988M | |
-20.60% | 910M | |
+2.36% | 786M | |
-24.02% | 634M |
- Stock Market
- Equities
- IMMNOV Stock
- 0G8X Stock